Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK56G0)

Drug Name

Bexagliflozin Drug Info

Synonyms

UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Approved	[1]
Type-2 diabetes	5A11	Phase 3	[2]

Cross-matching ID

PubChem CID: 25195624
ChEBI ID: CHEMBL1808388
CAS Number: CAS 1118567-05-7
TTD Drug ID: DMK56G0
VARIDT Drug ID: DR01083

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[4]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[5]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[5]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[6]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[6]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[5]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[6]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[6]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[6]
O-spiroketal glucoside	DM3FS62	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
UDP-glucuronosyltransferase 1A9	OTPCHAFX	UD19_HUMAN	Regulation of Drug Effects	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214373.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Bexagliflozin: First Approval. Drugs. 2023 Apr;83(5):447-453. doi: 10.1007/s40265-023-01848-x.
4	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
5	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
6	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
7	ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.